Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 7Lymphoma, T-Cell 3Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

liposomal amphotericin B 2Rituximab 2Levofloxacin 2Gemcitabine 2Early Intervention, Educational 2Doxorubicin 2Darbepoetin alfa 2ferrous sulfate 1ferric gluconate 1duvelisib 1belinostat 1Vincristine 1VAP-cyclo protocol 1Sucrose 1Radiotherapy 1Psychiatric Rehabilitation 1Prednisone 1Pharmacogenomic Testing 1Ondansetron 1Morphine 1Ketamine 1Hypericum extract LI 160 1Filgrastim 1Fentanyl 1Epoetin Alfa 1Drug Therapy 1Dextromethorphan 1Dexamethasone 1Dalteparin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Immunoblastic Lymphadenopathy × 10-propargyl-10-deazaaminopterin × Clear all
NCT06561048 2026-04-08

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Corvus Pharmaceuticals, Inc.

Phase 3 Recruiting
150 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡